Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
DNA test
MedTech
23andMe snags 3rd FDA nod for genetic cancer risk test
23andMe’s analysis can connect long-lost relatives, teach them about how DNA influences their lives and, now, determine their risk of prostate cancer.
Andrea Park
Jan 10, 2022 11:58am
Helix doubles down on COVID-19 surveillance with $50M series C
Jun 4, 2021 11:29am
23andMe to shut off third-party access to its genome API: CNBC
Aug 24, 2018 1:20pm
Diassess to get up to $21.9M to develop at-home flu diagnostic
Jul 17, 2018 3:56pm
Helix raises $200M series B for DNA test marketplace
Mar 8, 2018 8:26am
Helix debuts online marketplace for personal genomics products
Jul 24, 2017 11:16am